Investigational New Drugs

, Volume 29, Issue 5, pp 1102–1110

Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide

  • Catherine J. Drummond
  • Graeme J. Finlay
  • Laura Broome
  • Elaine S. Marshall
  • Emma Richardson
  • Bruce C. Baguley
SHORT REPORT

Summary

Aim: We have examined the cellular action of SN 28049 (N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide), a DNA binding drug with curative activity against the Colon 38 transplantable murine carcinoma, on human tumour cells. Its action has been compared with that of two topoisomerase II-targetted drugs, etoposide and doxorubicin. Methods: The NZM3 melanoma and HCT116 colon carcinoma cell lines, each expressing wild-type p53, were cultured and responses were compared by flow cytometry, electrophoresis, microscopy, and growth of tumour xenografts. Results: Responses of NZM3 cells to all three drugs, as measured by histone H2AX γ-phosphorylation, induction of the p53 pathway and cell cycle arrest, were comparable and typical of those of topoisomerase II poisons. Xenografts of NZM3 cells responded to SN 28049 with a tumour growth delay of 16 days. In contrast, HCT116 cells had an attenuated DNA damage response to the drugs and SN 28049 had no in vivo activity, consistent with low topoisomerase II activity. However, SN 28049 inhibited HCT116 cell growth in vitro and activated the p53 pathway to induce a state with G2/M-phase DNA content, low mitotic index and a high proportion of binucleate cells. Treated cells expressed cyclin E and the senescence marker β-galactosidase but showed low expression of cyclin B and survivin. In comparison, etoposide caused little p53 expression or cycle arrest, and doxorubicin had an intermediate effect. Conclusion: The action of SN 28049 in NZM3 cells is typical of a topoisomerase II poison, but the low topoisomerase IIα activity of HCT116 cells allowed the detection of a second antiproliferative action of SN 28049 in which cells undergo post-mitotic cycle arrest and induction of p53.

Keywords

Topoisomerase Chemotherapy Tetraploid Mitotic catastrophe Colon Melanoma 

References

  1. 1.
    Arcamone F (1985) Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture. Cancer Res 45:5995–5999PubMedGoogle Scholar
  2. 2.
    Stahelin HF, von Wartburg A (1991) The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain memorial award lecture. Cancer Res 51:5–15PubMedGoogle Scholar
  3. 3.
    Cain BF, Atwell GJ (1974) The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer Clin Oncol 10:539–549Google Scholar
  4. 4.
    Arlin ZA, Sklaroff RB, Gee TS, Kempin SJ, Howard J, Clarkson BD, Young CW (1980) Phase I and II trial of 4′-(9-acridinylamino) methanesulfon-m-anisidide in patients with acute leukemia. Cancer Res 40:3304–3306PubMedGoogle Scholar
  5. 5.
    Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, Wilson WR (1984) Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridinecarboxamide. Cancer Res 44:3245–3251PubMedGoogle Scholar
  6. 6.
    Harvey VJ, Hardy JR, Smith S, Grove W, Baguley BC (1991) Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer. Eur J Cancer 27:1617–1620PubMedCrossRefGoogle Scholar
  7. 7.
    McCrystal MR, Evans BD, Harvey VJ, Thompson PI, Porter DJ, Baguley BC (1999) Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 44:39–44PubMedCrossRefGoogle Scholar
  8. 8.
    Baguley BC, Zhuang L, Marshall E (1995) Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemother Pharmacol 36:244–248PubMedCrossRefGoogle Scholar
  9. 9.
    Deady LW, Rodemann T, Zhuang L, Baguley BC, Denny WA (2003) Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1, 6]naphthyridines. J Med Chem 46:1049–1054PubMedCrossRefGoogle Scholar
  10. 10.
    Deady LW, Rogers ML, Zhuang L, Baguley BC, Denny WA (2005) Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1, 6]naphthyridin-(5H)ones. Bioorg Med Chem 13:1341–1355PubMedCrossRefGoogle Scholar
  11. 11.
    Lukka PB, Paxton JW, Kestell P, Baguley BC (2010) Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemother Pharmacol 65:1145–1152PubMedCrossRefGoogle Scholar
  12. 12.
    Bridewell DJ, Porter AC, Finlay GJ, Baguley BC (2008) The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol 62:753–762PubMedCrossRefGoogle Scholar
  13. 13.
    Finlay GJ, Baguley BC, Snow K, Judd W (1990) Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J Natl Cancer Inst 82:662–667PubMedCrossRefGoogle Scholar
  14. 14.
    Marshall ES, Matthews JH, Shaw JH, Nixon J, Tumewu P, Finlay GJ, Holdaway KM, Baguley BC (1994) Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. Eur J Cancer 30A:1370–1376PubMedCrossRefGoogle Scholar
  15. 15.
    Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501PubMedCrossRefGoogle Scholar
  16. 16.
    Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC (2000) Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. Oncol Res 12:149–155PubMedGoogle Scholar
  17. 17.
    Deady LW, Kaye AJ, Finlay GJ, Baguley BC, Denny WA (1997) Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. J Med Chem 40:2040–2046PubMedCrossRefGoogle Scholar
  18. 18.
    Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858–5868PubMedCrossRefGoogle Scholar
  19. 19.
    Tanaka T, Huang X, Halicka HD, Zhao H, Traganos F, Albino AP, Dai W, Darzynkiewicz Z (2007) Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 71:648–661PubMedGoogle Scholar
  20. 20.
    Bridewell DJA, Finlay GJ, Baguley BC (1999) Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II. Cancer Chemother Pharmacol 43:302–308PubMedCrossRefGoogle Scholar
  21. 21.
    Shagisultanova EI, Piao Z, Li HR, Malkhosyan SR (2004) Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability. Cancer Lett 216:221–226PubMedCrossRefGoogle Scholar
  22. 22.
    Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng L, Zhang H, Pommier YA (2006) Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem 281:30814–30823PubMedCrossRefGoogle Scholar
  23. 23.
    van Leuken R, Clijsters L, Wolthuis R (2008) To cell cycle, swing the APC/C. Biochim Biophys Acta 1786:49–59PubMedGoogle Scholar
  24. 24.
    Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y (2005) Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 310:1499–1504PubMedCrossRefGoogle Scholar
  25. 25.
    Lanni JS, Jacks T (1998) Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18:1055–1064PubMedGoogle Scholar
  26. 26.
    Okada H, Mak TW (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4:592–603PubMedCrossRefGoogle Scholar
  27. 27.
    Tritarelli A, Oricchio E, Ciciarello M, Mangiacasale R, Palena A, Lavia P, Soddu S, Cundari E (2004) p53 localization at centrosomes during mitosis and postmitotic checkpoint are ATM-dependent and require serine 15 phosphorylation. Mol Biol Cell 15:3751–3757PubMedCrossRefGoogle Scholar
  28. 28.
    Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H (2004) Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23:6845–6853PubMedCrossRefGoogle Scholar
  29. 29.
    Demidenko ZN, Kalurupalle S, Hanko C, Lim CU, Broude E, Blagosklonny MV (2008) Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene 27:4402–4410PubMedCrossRefGoogle Scholar
  30. 30.
    Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247–3257PubMedCrossRefGoogle Scholar
  31. 31.
    Luo K, Yuan J, Chen J, Lou Z (2009) Topoisomerase IIalpha controls the decatenation checkpoint. Nat Cell Biol 11:204–210PubMedCrossRefGoogle Scholar
  32. 32.
    Coelho PA, Queiroz-Machado J, Carmo AM, Moutinho-Pereira S, Maiato H, Sunkel CE (2008) Dual role of topoisomerase II in centromere resolution and aurora B activity. PLoS Biol 6:e207PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Catherine J. Drummond
    • 1
    • 2
  • Graeme J. Finlay
    • 1
  • Laura Broome
    • 1
  • Elaine S. Marshall
    • 1
  • Emma Richardson
    • 1
  • Bruce C. Baguley
    • 1
  1. 1.Auckland Cancer Society Research Centre, Faculty of Medical and Health SciencesThe University of AucklandAucklandNew Zealand
  2. 2.Northern Institute for Cancer Research, Medical SchoolNewcastle UniversityNewcastle upon TyneUK

Personalised recommendations